Skip to main content

Sigma-Aldrich, Oxford BioMedica Settle Litigation with Open Biosystems

NEW YORK (GenomeWeb News) – Sigma-Aldrich and Oxford BioMedica said today that they have settled their two-year-old litigation with Open Biosystems over patents covering lentiviral vector technology.
Sigma-Aldrich and Oxford agreed to dismiss their suit against Open Bio, and Open Bio agreed to dismiss its counterclaims. As part of the settlement, Open Bio will acquire certain licensing rights to patents covering the use of Oxford’s LentiVector technology in research activities.
Other details of the settlement were not disclosed by the firms.
The dispute began in mid-2006, when Sigma-Aldrich and Oxford sued Open Bio for allegedly infringing two US patents held by Oxford and exclusively licensed by Sigma-Aldrich. In their lawsuit, the co-plaintiffs contend that numerous Open Bio products, including its RNAi Consortium shRNA lentiviral library and its shRNAmir libraries, infringed the IP.
As reported by GenomeWeb Daily News sister publication RNAi News in late February, the firms had been negotiating a potential settlement. The US District Court overseeing the case granted the companies’ request for “a stay of the litigation in all respects, including but not limited to expert disclosures … [through] March 14, 2008, to allow settlement talks to proceed.”

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.